TP63、SOX2和KLF5建立核心调控回路控制食管鳞癌细胞系的表观遗传和转录模式
研究对8种食管鳞癌细胞系进行表观遗传和转录分析,鉴定TP63、SOX2和KLF5为核心调控转录因子,其调控的超级增强子回路影响细胞活力和基因表达。表观遗传抑制剂联合可减缓小鼠异种移植瘤生长。
要点
- TP63、SOX2和KLF5是食管鳞癌细胞系的核心调控转录因子。
- 核心调控因子介导的ALDH3A1超级增强子调控对食管鳞癌细胞活力必需。
- ARV-771与罗米地辛联合使小鼠异种移植瘤生长慢于单药。
核心结论
- 在食管鳞癌细胞系的表观遗传和转录分析中,发现转录因子TP63、SOX2和KLF5是核心调控网络的一部分,决定染色质可及性、表观遗传修饰和基因表达模式。
- 表观遗传抑制剂联合可减缓小鼠食管鳞癌细胞来源异种移植瘤的生长。
研究设计与样本
- 研究对8种食管鳞癌细胞系进行染色质免疫沉淀测序(H3K4me1、H3K4me3、H3K27ac)和转座酶可及染色质测定,以绘制增强子区域和可及染色质。
- 使用CRC_Mapper算法鉴定核心调控回路转录因子,并确定其中3种因子的基因组占据谱。
- 在食管鳞癌细胞系中,用小发夹RNA敲低转录因子表达,用CRISPR/Cas9基因组编辑破坏启动子和增强子区域,或分别用ARV-771和罗米地辛抑制溴结构域和超末端(BET)家族蛋白及组蛋白脱乙酰酶(HDAC)。
- 对食管鳞癌细胞系进行全转录组测序、免疫沉淀、免疫印迹、免疫组化和活力测定;用环状染色体构象捕获测序鉴定和验证远端增强子与启动子间相互作用。
- 给NOD-SCID小鼠注射修饰的食管鳞癌细胞,部分小鼠注射HDAC或BET抑制剂,测量异种移植瘤生长。
主要发现
- 鉴定出超级增强子调控回路和转录因子TP63、SOX2、KLF5为食管鳞癌细胞的核心调控因子。
- 核心调控因子介导的ALDH3A1超级增强子调控对食管鳞癌细胞活力必需。
- 观察到TP63启动子区域与功能性增强子之间的直接相互作用,由核心调控回路转录因子介导。
- 从食管鳞癌细胞中删除增强子区域降低核心调控回路转录因子表达并减少细胞活力;敲低每种核心调控回路转录因子也观察到相同结果。
- 用BET和HDAC抑制剂孵育食管鳞癌细胞破坏核心调控回路程序及表观遗传修饰;注射HDAC或BET抑制剂的小鼠食管鳞癌细胞系异种移植瘤更小;联合ARV-771和罗米地辛的小鼠异种移植瘤生长慢于单药治疗小鼠。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We investigated the transcriptome of esophageal squamous cell carcinoma (ESCC) cells, activity of gene regulatory (enhancer and promoter regions), and the effects of blocking epigenetic regulatory proteins. METHODS: We performed chromatin immunoprecipitation sequencing with antibodies against H3K4me1, H3K4me3, and H3K27ac and an assay for transposase-accessible chromatin to map the enhancer regions and accessible chromatin in 8 ESCC cell lines. We used the CRC_Mapper algorithm to identify core regulatory circuitry transcription factors in ESCC cell lines, and determined genome occupancy profiles for 3 of these factors. In ESCC cell lines, expression of transcription factors was knocked down with small hairpin RNAs, promoter and enhancer regions were disrupted by CRISPR/Cas9 genome editing, or bromodomains and extraterminal (BET) family proteins and histone deacetylases (HDACs) were inhibited with ARV-771 and romidepsin, respectively. ESCC cell lines were then analyzed by whole-transcriptome sequencing, immunoprecipitation, immunoblots, immunohistochemistry, and viability assays. Interactions between distal enhancers and promoters were identified and verified with circular chromosome conformation capture sequencing. NOD-SCID mice were given injections of modified ESCC cells, some mice where given injections of HDAC or BET inhibitors, and growth of xenograft tumors was measured. RESULTS: We identified super-enhancer-regulated circuits and transcription factors TP63, SOX2, and KLF5 as core regulatory factors in ESCC cells. Super-enhancer regulation of ALDH3A1 mediated by core regulatory factors was required for ESCC viability. We observed direct interactions between the promoter region of TP63 and functional enhancers, mediated by the core regulatory circuitry transcription factors. Deletion of enhancer regions from ESCC cells decreased expression of the core regulatory circuitry transcription factors and reduced cell viability; these same results were observed with knockdown of each core regulatory circuitry transcription factor. Incubation of ESCC cells with BET and HDAC disrupted the core regulatory circuitry program and the epigenetic modifications observed in these cells; mice given injections of HDAC or BET inhibitors developed smaller xenograft tumors from the ESCC cell lines. Xenograft tumors grew more slowly in mice given the combination of ARV-771 and romidepsin than mice given either agent alone. CONCLUSIONS: In epigenetic and transcriptional analyses of ESCC cell lines, we found the transcription factors TP63, SOX2, and KLF5 to be part of a core regulatory network that determines chromatin accessibility, epigenetic modifications, and gene expression patterns in these cells. A combination of epigenetic inhibitors slowed growth of xenograft tumors derived from ESCC cells in mice.
引用
- Jiang YY, Jiang Y, Li CQ, et al. TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines. Gastroenterology. 2020. PMID: 32619460. doi:10.1053/j.gastro.2020.06.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。